您当前的位置:
首页 >
文章列表页 >
miR-106b as an emerging therapeutic target in cancer
Review article | 更新时间:2022-06-24
    • miR-106b as an emerging therapeutic target in cancer

    • miR-106b as an emerging therapeutic target in cancer

    • Genes & Diseases   2022年9卷第4期
    • 作者机构:

      Department of Zoology, Swami Shraddhanand College, University of Delhi, Delhi,India,110036

    • DOI:10.1016/j.gendis.2021.02.002    

      中图分类号:
    • 纸质出版日期:2022,

      网络出版日期:2022-7-1,

    扫 描 看 全 文

  • Surendra Kumar Sagar. miR-106b as an emerging therapeutic target in cancer[J]. Genes & Diseases, 2022,9(4). DOI: 10.1016/j.gendis.2021.02.002.

    Surendra Kumar Sagar. miR-106b as an emerging therapeutic target in cancer[J]. Genes & Diseases, 2022,9(4). DOI: 10.1016/j.gendis.2021.02.002.

  •  
  •  
查看原文

0

浏览量

0

下载量

0

CSCD

文章被引用时,请邮件提醒。
提交
工具集
下载
参考文献导出
分享
收藏
添加至我的专辑

相关文章

MicroRNA-9 as a paradoxical but critical regulator of cancer metastasis: Implications in personalized medicine
Autophagy-related lncRNAs in tumor progression and drug resistance: A double-edged sword
DEAD-box RNA helicases with special reference to p68: Unwinding their biology, versatility, and therapeutic opportunity in cancer
A novel aptamer-based small RNA delivery platform and its application to cancer therapy
Chaperone-assisted E3 ligase CHIP: A double agent in cancer

相关作者

Yichen Liu
Qiong Zhao
Tao Xi
Lufeng Zheng
Xiaoman Li
Yunchao Zhang
Jiayu Tang
Cheng Wang

相关机构

Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine
School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, 639 Longmian Road
School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine
School of Pharmacy, Chengdu University of Traditional Chinese Medicine
Institute of Translational Pharmacology and Clinical Application, Sichuan Academy of Chinese Medical Science
0